Science

May 12, 2025, 09:12

Myeloma Paper of the Day, May 12th, suggested by Robert Orlowski

Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:

“Myeloma Paper of the Day: Duke experience of belantamb mafodotin shows ORR of 67%, median PFS 9.5 months, median OS NR at 3-years, cycle delay in 28 (93%) with 85% due to ocular AEs (2% grade ≥3), treatment discontinuation from ocular tox in 4 (13%).”

Title: Treatment Patterns, Efficacy, and Tolerability of Belantamab Mafodotin in Patients With Relapsed and/or Refractory Multiple Myeloma: A Real-World Analysis

Authors: Mihir N. Patel, Susan C. Locke, Caroline Falvey, Jesse D. Troy, Kris W. Herring, Amanda Bolgioni-Smith, Cherie Elcock, Laura Iadeluca, Cristiana Costa Chase, Cristina Gasparetto, Mark S. Newman, Thomas W. LeBlanc

Read the Full Article in Clinical Lymphoma, Myeloma and Leukemia.

More posts featuring Robert Orlowski.

Amanda Bolgioni-Smith belantamb mafodotin cancer Caroline Falvey Cherie Elcock Cristiana Costa Chase Cristina Gasparetto Jesse D. Troy Kris W. Herring Laura Iadeluca Mark S. Newman Mihir N. Patel multiple myeloma Myeloma Paper of the Day OncoDaily Oncology Robert Orlowski RRMM Susan C. Locke Thomas W. LeBlanc

Oncologist Near Me – Wafik S. El-Deiry: A Global Leader in Translational Oncology and Cancer Research

In Memory of Bob Marley: His Battle with Melanoma and the Importance of Early Detection

Who From Oncology is Featured in TIME100 Health 2025?

FDA Announces Aggressive Timeline to Scale 1st AI-Assisted Scientific Review Pilot

The Evolving Therapeutic Revolution in Adult Acute Lymphoblastic Leukemia